Table 4.
Baseline clinical profiles and responses after CHP-NY-ESO-1 vaccinations
|
100 μg |
200 μg |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| pt No. | Response to previous therapies (duration time, weeks) | *sum of tumor diameters (mm) | Tumor response (BOR) | Time-to-progression (weeks) | Survival (weeks) | pt No. | Response to previous therapies (duration time, weeks) | *sum of tumor diameters (mm) | Tumor response (BOR) | Time-to-progression (weeks) | Survival (weeks) |
| 100-01 |
PR (4) |
NA |
PD |
6 |
31 |
200-01 |
PR (29) |
24 |
SD |
17 |
70 |
| 100-02 |
SD |
53 |
NE |
4 |
6 |
200-02 |
NE |
25 |
SD |
18 |
33 |
| 100-03 |
NE |
144 |
NE |
4 |
6 |
200-03 |
PR (32) |
55 |
PD |
6 |
37 |
| 100-04 |
PD |
182 |
PD |
5 |
17 |
200-04 |
PR (30) |
NA |
PD |
6 |
50 |
| 100-05 |
CR (38) |
101 |
NE |
4 |
4 |
200-05 |
PR (32) |
NA |
PD |
6 |
72 |
| 100-06 |
SD |
69 |
PD |
6 |
31 |
200-06 |
NE |
32 |
SD |
18 |
54 |
| 100-07 |
CR (15) |
78 |
PD |
6 |
29 |
200-07 |
NE |
205 |
NE |
6 |
8 |
| 100-08 |
NE |
39 |
SD |
18 |
23 |
200-08 |
PR (12) |
16 |
SD |
11 |
33 |
| 100-09 |
SD |
18 |
PD |
6 |
8 |
200-09 |
CR (96) |
88 |
PD |
6 |
45 |
| 100-10 |
CR (24) |
NA |
SD |
11 |
60 |
200-10 |
SD |
NA |
SD |
12 |
48 |
| 100-11 |
SD |
31 |
SD |
12 |
20 |
200-11 |
SD |
NA |
NE |
6 |
12 |
| 100-12 |
PR (9) |
NA |
NE |
16 |
28 |
200-12 |
SD |
NA |
SD |
12 |
33 |
| 100-13 | PR (16) | NA | NE | 52 | 59 | ||||||
*target lesions determined based on RECIST criteria.